Towards establishing the standard of care for second-line therapy in advanced biliary tract cancer

The prognosis of patients with advanced biliary tract cancer is poor. Preferred first-line chemotherapy for these patients is a combination of gemcitabine plus cisplatin, following the results of the ABC-02 trial.1 The ABC-06 trial2 compared active symptom control with active symptom control and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) in patients with advanced biliary tract cancer who had progressed on gemcitabine plus cisplatin, and showed improved overall survival with the addition of FOLFOX.